AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14643741 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct victimization at home by the father (for boys) and by both parents (for girls)
Number of subjects: 998
Study 11177199 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFAT (1.2 g saturated fat/kg BM with 3500 U heparin intravenously)
Number of subjects: 7
Study 11177199 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (2.5 g carbohydrate/kg BM)
Number of subjects: 7
Study 11177199 — intervention group
Group type: EXPERIMENTAL
Intervention: NA (2.5 g carbohydrate + 20 mg nicotinic acid/kg BM)
Number of subjects: 7
Study 11177199 — intervention group
Group type: COMPARATOR
Intervention: HIFAT
Number of subjects: 7
Study 11177199 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 7
Study 8994707 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent placement (n = 107)
Number of subjects: 213
Study 8994707 — intervention group
Group type: COMPARATOR
Intervention: Primary PTA (n = 106)
Number of subjects: 213
Study 8994707 — intervention group
Group type: COMPARATOR
Intervention: PTA plus selective stent placement
Number of subjects: 213
Study 1482131 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (beta-lactam plus aminoglycoside)
Number of subjects: 230
Study 1482131 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (beta-lactam or aminoglycoside)
Number of subjects: 230
Study 4018499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine bolus administration (up to 300 mg every 6 h, 1200 mg/day)
Number of subjects: 23
Study 4018499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine primed infusion (up to 50 mg/h, 1200 mg/day)
Number of subjects: 23
Study 4018499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (both methods)
Number of subjects: 23
Study 4018499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine infusion
Number of subjects: 23
Study 4018499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (therapeutic levels)
Number of subjects: 23
Study 29036480 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandible advanced device (MAD) therapy
Number of subjects: 30
Study 29036480 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 29036480 — intervention group
Group type: COMPARATOR
Intervention: Group OSAHS (induced OSAHS without treatment)
Number of subjects: 30
Study 27343983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture-derived trivalent influenza vaccine (TIVc)
Number of subjects: 430
Study 27343983 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-derived trivalent influenza vaccine (TIV)
Number of subjects: 430
Study 27343983 — intervention group
Group type: COMPARATOR
Intervention: Both TIVc and TIV
Number of subjects: 430
Study 25045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Google search queries
Number of subjects: 0
Study 25045360 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-based combined symptom medication score
Number of subjects: 0
Study 21864865 — intervention group
Group type: COMPARATOR
Intervention: Exercise with placebo (EX + PL)
Number of subjects: 52
Study 21864865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with phytoestrogens (EX + PHY)
Number of subjects: 52
Study 20159380 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional microarray (FMA) applied to one forearm
Number of subjects: 25
Study 20159380 — intervention group
Group type: COMPARATOR
Intervention: Sham device applied to the other forearm
Number of subjects: 25
Study 18826358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (1.25-5 mg/kg/day) administered intravenously, initiated within 8 hours of injury, in 2 divided doses or continuous infusion over 72 hours.
Number of subjects: 40
Study 18826358 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, initiated within 8 hours of injury.
Number of subjects: 40
Study 16193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) 0.31 mg
Number of subjects: 211
Study 16193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) 0.63 mg
Number of subjects: 211
Study 16193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol (RAC) 1.25 mg (for children <33 lb)
Number of subjects: 211
Study 16193496 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol (RAC) 2.5 mg (for children >/=33 lb)
Number of subjects: 211
Study 16193496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 211
Study 12421065 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular viewing
Number of subjects: 0
Study 12421065 — intervention group
Group type: COMPARATOR
Intervention: Monocular viewing
Number of subjects: 0
Study 10359887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate powder, 500 microgram, twice daily
Number of subjects: 64
Study 10359887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7677297 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to thyroid hormone
Number of subjects: 104
Study 2371802 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in emulsion (Diprivan) - bolus of 2 mg/kg followed by infusion of 6 mg/kg/h for one hour.
Number of subjects: 20
Study 2371802 — intervention group
Group type: COMPARATOR
Intervention: Intralipid 10% - bolus of 0.2 mg/kg followed by infusion of 0.6 ml/kg/h for one hour.
Number of subjects: 20
Study 6164204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamin and low-dose heparin (DHEH)
Number of subjects: 357
Study 6164204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphated polysaccharid (PZ68B)
Number of subjects: 357
Study 6164204 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 357
Study 31404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg (more than 12 months exposure)
Number of subjects: 1758
Study 31404668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (more than 12 months exposure)
Number of subjects: 1758
Study 31082305 — intervention group
Group type: EXPERIMENTAL
Intervention: UAV-assisted scouting using multispectral imaging
Number of subjects: 0
Study 31082305 — intervention group
Group type: COMPARATOR
Intervention: Conventional scouting
Number of subjects: 0
Study 31082305 — intervention group
Group type: EXPERIMENTAL
Intervention: UAV-assisted scouting
Number of subjects: 0
Study 27845858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 27845858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25392071 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (n=255)
Number of subjects: 508
Study 25392071 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (n=253)
Number of subjects: 508
Study 25392071 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 508
Study 23708038 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew
Number of subjects: 20
Study 23708038 — intervention group
Group type: COMPARATOR
Intervention: Conventional utility arch
Number of subjects: 20
Study 21250762 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 15
Study 21250762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19548407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced adjustable mandibular advancement appliance (MAA) at 25% protrusion
Number of subjects: 12
Study 19548407 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced adjustable mandibular advancement appliance (MAA) at 75% protrusion
Number of subjects: 12
Study 19548407 — intervention group
Group type: COMPARATOR
Intervention: Mandibular occlusal splint (MOS)
Number of subjects: 12
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9/TIMP-1 ratio in patients with volume overload
Number of subjects: 0
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 levels in patients with pressure overload
Number of subjects: 0
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9/TIMP-1 coefficient
Number of subjects: 0
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 content in patients with aortic stenosis
Number of subjects: 0
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of MMP-9 and MMP-9/TIMP-1 ratio
Number of subjects: 0
Study 18260979 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of MMP-9 and TIMP-1
Number of subjects: 0
Study 12955096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide administered subcutaneously at 2245
Number of subjects: 7
Study 12955096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11449530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (Ibec) - 2 puffs/12 hr, 100 micrograms per puff
Number of subjects: 29
Study 11449530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone-salmeterol (Ibe + Isal) - Beclomethasone 2 puffs/12 hr, 100 micrograms per puff and Salmeterol 2 puffs/12 hr, 25 micrograms per puff
Number of subjects: 29
Study 11449530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (Ibec)
Number of subjects: 29
Study 11449530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone-salmeterol (Ibe + Isal)
Number of subjects: 29
Study 11832140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine (T group)
Number of subjects: 42
Study 11832140 — intervention group
Group type: COMPARATOR
Intervention: No Anisodamine (C group)
Number of subjects: 42
Study 8880076 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 60
Study 8880076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1839434 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 6841391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with induced hypotension using sodium nitroprusside and trimetaphan
Number of subjects: 44
Study 6841391 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthesia without induced hypotension
Number of subjects: 44
Study 29723124 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation assessment
Number of subjects: 47
Study 29723124 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 47
Study 29622393 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in the ED waiting room before seeing the emergency physician, followed by a 30-day telephone follow-up.
Number of subjects: 94
Study 29622393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 94
Study 26402918 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg, increased to 400 mg if uncontrolled after 2 weeks, with optional addition of another antihypertensive drug after 4 weeks (n=21)
Number of subjects: 35
Study 24821628 — intervention group
Group type: EXPERIMENTAL
Intervention: L-bent-level gesture
Number of subjects: 420
Study 24821628 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no gesture)
Number of subjects: 420
Study 22311378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 22
Study 22311378 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava (180 mg of kavalactones)
Number of subjects: 22
Study 22311378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20424465 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at 10 Hz and 90% motor threshold intensity
Number of subjects: 10
Study 20424465 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 10
Study 18594000 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (260 mg/m² as a 30-minute infusion)
Number of subjects: 17
Study 18594000 — intervention group
Group type: COMPARATOR
Intervention: sb-paclitaxel (175 mg/m² as a 3-hour infusion)
Number of subjects: 17
Study 15959923 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary astrocytomas
Number of subjects: 46
Study 15959923 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningiomas
Number of subjects: 46
Study 15959923 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent astrocytomas
Number of subjects: 46
Study 15959923 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent low-grade astrocytomas
Number of subjects: 46
Study 11952043 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-T2 signal intensity (SI) assessment
Number of subjects: 39
Study 11952043 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-T2 pattern assessment
Number of subjects: 39
Study 10495459 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care service delivered by one type of medical doctor
Number of subjects: 0
Study 10495459 — intervention group
Group type: COMPARATOR
Intervention: Primary care service delivered by another type of medical doctor
Number of subjects: 0
Study 7721556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily baths in the Dead Sea (Group 1, n = 9)
Number of subjects: 36
Study 7721556 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sulphur baths (Group 2, n = 9)
Number of subjects: 36
Study 7721556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of daily Dead Sea bathing and sulphur baths (Group 3, n = 10)
Number of subjects: 36
Study 7721556 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 4, n = 8)
Number of subjects: 36
Study 2116440 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 125 micrograms
Number of subjects: 12
Study 2116440 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 250 micrograms
Number of subjects: 12
Study 2116440 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 500 micrograms
Number of subjects: 12
Study 2116440 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 750 micrograms
Number of subjects: 12
Study 2116440 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1000 micrograms
Number of subjects: 12
Study 2116440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30378759 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGM threshold at 90 mg/dL during exercise
Number of subjects: 34
Study 30378759 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGM threshold at 70 mg/dL during exercise
Number of subjects: 34
Study 30378759 — intervention group
Group type: COMPARATOR
Intervention: PLGM system (both thresholds)
Number of subjects: 34
Study 29718777 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Specific Balance Training (TSBT), 60 minutes per session, three times a week for 12 months
Number of subjects: 100
Study 29718777 — intervention group
Group type: COMPARATOR
Intervention: Task-Specific Balance Training (TSBT)
Number of subjects: 100
Study 26961741 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise program consisting of muscle strength exercises and endurance training.
Number of subjects: 107
Study 26961741 — intervention group
Group type: COMPARATOR
Intervention: Standard group (control).
Number of subjects: 107
Study 25310120 — intervention group
Group type: EXPERIMENTAL
Intervention: POC Plus (point-of-care CD4 devices and related counseling support)
Number of subjects: 0
Study 25310120 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (routine, laboratory-based CD4 testing)
Number of subjects: 0
Study 22649214 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 294
Study 22649214 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 294
Study 20181504 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill training involving isolated voluntary contractions of transversus abdominis (TrA) for 2 weeks
Number of subjects: 20
Study 20181504 — intervention group
Group type: COMPARATOR
Intervention: Self-paced walking exercise for 2 weeks
Number of subjects: 20
Study 18175604 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization in experimental design
Number of subjects: 0
Study 18175604 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15608053 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (zidovudine/lamivudine and efavirenz)
Number of subjects: 53
Study 15608053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (zidovudine/lamivudine/abacavir and efavirenz)
Number of subjects: 53
Study 12145057 — intervention group
Group type: COMPARATOR
Intervention: IV atropine 10 microg/kg
Number of subjects: 61
Study 12145057 — intervention group
Group type: COMPARATOR
Intervention: IV atropine 20 microg/kg
Number of subjects: 61
Study 10532982 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2B (3 x 10(6) IU per day)
Number of subjects: 21
Study 10532982 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study 8829846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective angiography
Number of subjects: 56
Study 8829846 — intervention group
Group type: COMPARATOR
Intervention: Selective angiography
Number of subjects: 56
Study 2108751 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin to achieve a haemoglobin concentration of 95‐110 g/l (n = 40)
Number of subjects: 118
Study 2108751 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin to achieve a haemoglobin concentration of 115‐130 g/l (n = 38)
Number of subjects: 118
Study 2108751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 118
Study 7352279 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg/day)
Number of subjects: 0
Study 7352279 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 mg/day)
Number of subjects: 0
Study 7352279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30968588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NEPA (netupitant-palonosetron 300/0.50 mg)
Number of subjects: 1862
Study 30968588 — intervention group
Group type: COMPARATOR
Intervention: Oral palonosetron 0.50 mg
Number of subjects: 1862
Study 30968588 — intervention group
Group type: COMPARATOR
Intervention: Oral aprepitant 125 mg day 1, 80 mg days 2-3/palonosetron 0.50 mg
Number of subjects: 1862
Study 27707593 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 205
Study 27707593 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 205
Study 27707593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 27707593 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (both doses)
Number of subjects: 205
Study 26486525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (IAD)
Number of subjects: 114
Study 26486525 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (CAD)
Number of subjects: 114
Study 25622671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 µg calcitriol daily
Number of subjects: 164
Study 25622671 — intervention group
Group type: COMPARATOR
Intervention: Control group (original treatment regimen)
Number of subjects: 164
Study 21385791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 41778
Study 19717850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 3690
Study 19717850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3690
Study 15698698 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐Breeze collar
Number of subjects: 20
Study 15698698 — intervention group
Group type: EXPERIMENTAL
Intervention: Miami J collar
Number of subjects: 20
Study 15698698 — intervention group
Group type: EXPERIMENTAL
Intervention: XTW collar
Number of subjects: 20
Study 15698698 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen collar
Number of subjects: 20
Study 12833245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pulses of methylprednisolone (MEP)
Number of subjects: 0
Study 12833245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard dose of 1 g/day for 3 consecutive days of MEP
Number of subjects: 0
Study 12833245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of MEP
Number of subjects: 0
Study 10036892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injected through a central venous catheter (group A, n = 13)
Number of subjects: 39
Study 10036892 — intervention group
Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B, n = 13)
Number of subjects: 39
Study 10036892 — intervention group
Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C, n = 13)
Number of subjects: 39
Study 10036892 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injected through a central venous catheter (group A)
Number of subjects: 39
Study 10036892 — intervention group
Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula without carrier intravenous fluid (group B)
Number of subjects: 39
Study 10036892 — intervention group
Group type: COMPARATOR
Intervention: Propofol injected through a peripheral cannula with rapid infusion of acetated Ringer's solution (group C)
Number of subjects: 39
Study 8694599 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits (HBC) with lower anticoagulation therapy (activated clotting time > 280 seconds)
Number of subjects: 234
Study 8694599 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits (HBC) with lower anticoagulation therapy
Number of subjects: 234
Study 8694599 — intervention group
Group type: COMPARATOR
Intervention: Conventional, nonheparin-bonded circuits with full anticoagulation therapy (activated clotting time > 480 seconds)
Number of subjects: 234
Study 1831686 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with three-monthly scale and polish and reinforcement of oral hygiene instruction (Group 3)
Number of subjects: 382
Study 1831686 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supervised toothbrushing with one-monthly input from a dental hygienist (Group 4)
Number of subjects: 382
Study 1831686 — intervention group
Group type: COMPARATOR
Intervention: Daily supervised toothbrushing without additional treatment (Control group)
Number of subjects: 382